Nicholas M. Durham
AstraZeneca (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Glioma Diagnosis and Treatment, Immune cells in cancer
Most-Cited Works
- → Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant(2021)1,318 cited
- → Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas(2013)893 cited
- → Targeting CD73 in the tumor microenvironment with MEDI9447(2016)283 cited
- → A role for the transcription factor Helios in human CD4+CD25+ regulatory T cells(2010)249 cited
- → Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model(2014)236 cited
- → Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo(2014)185 cited
- → Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models(2015)172 cited
- → Phenotypic and Functional Properties of Helios+ Regulatory T Cells(2012)164 cited
- → Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa(2021)122 cited
- → AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T H 1 response with a diverse TCR repertoire(2021)106 cited